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Abstract
We show that extracellular vesicles (EVs) released by mesenchymal
cells (i.e., fibro–adipogenic progenitors—FAPs) mediate microRNA
(miR) transfer to muscle stem cells (MuSCs) and that exposure of
dystrophic FAPs to HDAC inhibitors (HDACis) increases the intra-EV
levels of a subset of miRs, which cooperatively target biological
processes of therapeutic interest, including regeneration, fibrosis,
and inflammation. Increased levels of miR-206 in EVs released by
FAPs of muscles from Duchenne muscular dystrophy (DMD) patients
or mdx mice exposed to HDACi are associated with enhanced
regeneration and decreased fibrosis. Consistently, EVs from HDACi-
treated dystrophic FAPs can stimulate MuSC activation and expan-
sion ex vivo, and promote regeneration, while inhibiting fibrosis
and inflammation of dystrophic muscles, upon intramuscular trans-
plantation in mdx mice, in vivo. AntagomiR-mediated blockade of
individual miRs reveals a specific requirement of miR-206 for EV-
induced expansion of MuSCs and regeneration of dystrophic
muscles, and indicates that cooperative activity of HDACi-induced
miRs accounts for the net biological effect of these EVs. These data
point to pharmacological modulation of EV content as novel strat-
egy for therapeutic interventions in muscular dystrophies.
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Introduction
Emerging evidence indicates that reciprocal interactions between
distinct cellular components of the regeneration “machinery” generate
either a productive or a hostile environment for regeneration of
dystrophic muscles (Moyer & Wagner, 2011; Tidball, 2011; Farup et al,
2015). While muscle stem (satellite) cells (Mauro, 1961) (therein indi-
cated as MuSCs) are the direct effectors of muscle repair, a variety of
other cell types contribute to muscle regeneration, by spatially and
temporally coordinating the activity of MuSCs (Bentzinger et al, 2013;
Dumont et al, 2015b). These cells comprise components of the
inflammatory infiltrate, including macrophages and eosinophils
(Kharraz et al, 2013; Tidball et al, 2014), and a heterogeneous popula-
tion of muscle-derived interstitial cells referred to as fibro–adipogenic
progenitors (FAPs) (Joe et al, 2010; Uezumi et al, 2010; Malecova et al,
2018). Disruption of this network compromises the integrity of MuSC
niche and has been associated with the progression of many chronic
muscular disorders (i.e., muscular dystrophies) and age-related decline
in muscle mass and repair (Uezumi et al, 2011; Blau et al, 2015).
Upon myofiber damage, FAP accumulation is preceded by the
appearance of the inflammatory infiltrate and is followed by MuSC
activation (Heredia et al, 2013; Lemos et al, 2015). This temporal
1 Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione Santa Lucia, Rome, Italy
2 Division DAHFMO, Unit of Histology and Medical Embryology, Sapienza University of Rome, Rome, Italy
3 Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, Rome, Italy
4 IRCCS San Raffaele Pisana, Rome, Italy
5 Orchidea Lab S.r.l., Rome, Italy
6 Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council (CNR) of Italy, Palermo, Italy
7 Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children’s Hospital, Rome, Italy
8 Clinical R&D Italfarmaco SpA, Cinisello Balsamo, Italy
9 Development, Aging and Regeneration Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
10 Dipartimento Scienze della Vita e Sanità Pubblica, Università Cattolica del Sacro Cuore, Rome, Italy
*Corresponding author. Tel: +1 (858) 646-3100; E-mail: lpuri@sbpdiscovery.org
**Corresponding author. Tel: +39 (06) 501703266; E-mail: v.saccone@hsantalucia.it
†These authors contributed equally to this work
ª 2020 The Authors EMBO reports e50863 | 2020 1 of 19
pattern suggests a key role for FAPs in converting inflammatory
cues into signals that regulate MuSC activity, and implies reciprocal
communications between these cell types, through the exchange of
soluble mediators, which are largely unknown. Deciphering the
molecular and functional identity of these mediators might reveal
selective targets for interventions aimed at restoring functional inter-
actions between cellular components of the skeletal muscle environ-
ment during maladaptive repair in chronic muscular disorders.
Previous studies identified FAPs as key cellular targets of histone
deacetylase inhibitor (HDACi)—a pharmacological intervention that
counters DMD progression by promoting compensatory regenera-
tion, while inhibiting fibro–adipogenic degeneration both in pre-
clinical studies (Minetti et al, 2006; Consalvi et al, 2011, 2013,
2016; Mozzetta et al, 2013; Saccone et al, 2014; Sandoná et al,
2016) and in clinical trials (Bettica et al, 2016). While these studies
indicate the pharmacological potential of HDACi to restore the
regenerative environment in dystrophic muscles, by recovering
physiological functional interactions between FAPs and other cellu-
lar components (Consalvi et al, 2014), the signals that mediate
HDACi ability to restore physiological interactions between FAPs
and other cell types in DMD muscles remain largely unknown.
Here, we report the identification and functional characterization of
extracellular vesicles (EVs) that mediate FAP’s ability to promote MuSC
activation and differentiation, as well as to inhibit muscle fibrosis and
inflammation, in DMD muscles exposed to HDACi, through the cooper-
ative activities of miR-206 and other HDACi-induced intra-EV miRs.
Results
EVs mediate FAP ability to promote MuSCs activation and
differentiation upon exposure to HDACi
The pan-HDACi Givinostat (Giv) is the first “epigenetic” drug that
has been used in a clinical trial with DMD boys (Bettica et al, 2016).
Histological analysis of muscles from patients treated with Giv
showed increased regeneration, with a concomitant decrease in
fibrosis and fat infiltration, akin to the effects previously observed
in pre-clinical studies with mdx mice (the mouse model of DMD)
treated with pan-HDACi, such as Giv or Trichostatin A (TSA)
(Minetti et al, 2006; Consalvi et al, 2013). In addition to the histo-
logical analysis, we also obtained access to representative fresh
biopsies from 2 DMD patients, before and after Giv treatment, from
which we isolated by FACS two populations of our main interest—
human MuSCs (CD11bneg, CD31neg, CD45neg, CD56/NCAMpos)
and a population mesenchymal cells enriched in presumptive
human FAPs (CD11bneg, CD31neg, CD45neg, CD56/NCAMneg).
Figure EV1A shows that patient-derived human MuSCs (hMuSCs)
could form myotubes when cultured in vitro; likewise, the cell popu-
lation enriched in human FAPs (ehFAPs) could differentiate into
adipocytes in vitro, when cultured in adipogenic medium. The avail-
ability of these patient-derived cells provides an unprecedented
opportunity to evaluate the effect of HDACi on MuSC-FAPs interac-
tions ex vivo and in vivo. Ex vivo experiments were performed by
transwell co-culture of hMuSCs and ehFAPs from patients before the
beginning of the clinical trial. In both patients, co-culture with
ehFAPs slightly decreased hMuSC ability to differentiate into multin-
ucleated myotubes (Fig 1A and B). This is in contrast with the
reported ability of FAPs isolated from 2-month-old mdx mice to
promote differentiation of MuSCs from the same animal (Mozzetta
et al, 2013). The discrepancy between these results is likely
accounted for by differences of DMD progression between human
patients and mouse models, with 8- to 11-year-old patients enrolled
in the clinical trial being at more advanced stages of disease progres-
sion, as also shown by the more pronounced fibrosis observed in
their muscles, as compared to 2-month-old mdx mice. Exposure of
ehFAPs to Giv (ehFAPs Giv Vitro) prior to co-culture with hMuSCs
could increase the formation of hMuSC-derived myotubes to an
extent comparable to that observed in hMuSCs isolated from
patients after 1 year of Giv treatment in vivo (hMuSCs Giv) (Fig 1A
▸Figure 1. HDACi restores DMD FAP ability to support to MuSC differentiation into multinucleated myotubes.A Representative images showing the myogenic differentiation, as assessed by immunostaining for MyHC (green), of human MuSCs (hMuSCs) isolated from muscle
biopsies of DMD patients, either before the beginning of the clinical trial (hMuSCs ()) or after 1 year of treatment with Givinostat (hMuSCs Giv ()). Cells were
cultured alone or (only for hMuSCs ()) in transwell co-culture with FAPs isolated from the same patients and exposed in vitro to Giv (+ehFAPs Giv Vitro) or control
vehicle (+ehFAPs). The upper panels represent myogenic differentiation of DMD-1 patient; bottom panels represent myogenic differentiation of DMD-2 patient. Dose
and timing of Giv treatment as described in Bettica et al (2016). Scale bar = 50 lm.
B Graph showing the differentiation index of hMuSCs described in (A). Two technical replicates are shown.
C Representative images showing the myogenic differentiation of MuSCs isolated from 1.5-month-old mdx mice, as assessed by immunostaining for MyHC (green).
MuSCs were cultured alone () or in transwell co-culture with mdx FAPs, which were pre-treated with DMSO or GW4869 (GW 10 mM added to FAPs 30 min before
starting the co-culture with MuSCs). Scale bar = 50 lm.
D Graph showing the fusion index of MuSCs in the conditions described in (C), (n = 5, biological replicates). Star (*) indicates statistical analysis by Tukey’s test relative
to MuSCs cultured alone (), **P < 0.01; hash (#) indicates statistical analysis by Tukey’s test relative to MuSCs in co-cultured with FAPs not treated (DMSO),
#P < 0.05; § represents statistical analysis by two-way ANOVA test; §§§P < 0.001.
E Representative images of PKH-67 (green) and DAPI (blue) staining in a transwell co-culture between MuSCs and FAPs isolated from 1.5-month-old mdx mice. FAPs
exposed to PKH-67 prior to the co-culture with MuSCs. Scale bar = 50 lm.
F Graph showing the percentage of PKH-67-positive MuSCs after the co-culture with FAPs, (n = 3, biological replicates). Star (*) indicates statistical analysis by t-test;
****P < 0.0001.
G Representative images of myogenic differentiation of mdx MuSCs, as assessed by immunostaining for MyHC (green). MuSCs were cultured either alone () or incubated
with EVs isolated from 1.5-month-old mdx mice (EVs-FAPs) treated with vehicle (CTR) or exposed to TSA in vivo (TSA) or in vitro (TSA vitro). Scale bar = 50 lm.
H Graph showing the fusion index of MuSCs in the condition described in (G), (n = 3, biological replicates). Star (*) indicates statistical analysis by Tukey’s test on the %
of n > 5 (% of nuclei that were MyHC+ inside myotubes containing more than 5 nuclei) relative to MuSCs cultured alone (), **P < 0.01, ****P < 0.0001; hash (#)
indicates statistical analysis by Tukey’s test relative to EVs-FAPs CTR, ##P < 0.01, ###P < 0.001; ns = not significant; § represents statistical analysis by two-way
ANOVA test, §§§§P < 0.0001.
Data information: Nuclei were counterstained with DAPI (blue). All data correspond to the average  SEM.
2 of 19 EMBO reports e50863 | 2020 ª 2020 The Authors
EMBO reports Martina Sandonà et al
and B). These data indicate that FAP’s ability to support MuSC dif-
ferentiation is compromised in muscles of DMD patients, but can be
recovered upon treatment with HDACi.
To determine the identity of the extracellular mediators of the
functional interactions between FAPs and MuSCs in DMD muscles,
we performed transwell co-cultures of these cells isolated from the
mouse model of Duchenne muscular dystrophy (DMD)—the mdx
mice. FAPs were isolated from 1.5-month-old mdx mice and were
co-cultured with MuSCs isolated from age-matched mdx mice. In
transwell cultures, cells are separated by a membrane of 1 lm pore
size that prevents direct cell contact, yet allows reciprocal transfer of
soluble mediators—e.g., growth factors and cytokines, as well as
extracellular vesicles (EVs), such as exosomes—that are exchanged
between co-cultured cells. FAPs enhanced the ability of co-cultured
MuSCs to differentiate into multinucleated myotubes, as compared
to MuSCs cultured alone (Fig 1C and D), as previously reported
(Mozzetta et al, 2013); however, exposure of FAPs to the neutral
sphingomyelinase inhibitor GW4869, which selectively blocks
exosome biogenesis (Trajkovic et al, 2008), prior to co-culture with
MuSCs, abrogated FAP’s ability to enhance MuSC differentiation into
multinucleated myotubes (Fig 1C and D). This evidence indicates
that EVs are essential contributors of FAP-mediated support to MuSC
activity and implies that FAP-delivered EV/exosomes are transferred
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We next isolated EVs from FAP’s supernatant and analyzed
their size distribution by dynamic light scattering (DLS) experi-
ments. To this purpose, we have compared two purification
procedures: (i) a commercially available Total Exosome IsolationTM
precipitation Reagent (TEIR) and (ii) the current gold standard
isolation method, which is based on differential ultracentrifuga-
tions (UC) (Théry et al, 2006; Van Deun et al, 2014). DLS analy-
ses showed for both FAP-derived vesicle preparations an average
hydrodynamic diameter of about 150 nm that is consistent with
the standard size of exosomes (Fig EV1B) (Raposo & Stoorvogel,
2013). DLS analysis was also complemented with scanning elec-
tron microscopy (SEM) analyses of fixed TEIR-isolated EVs that
showed round-shaped FAP-derived EVs ranging from 100 to
150 nm in size (Fig EV1C). The slight difference in size between
SEM and DLS analyses can be explained by the fact that DLS
measures the hydrodynamic diameter of native particles in disper-
sion and is inherently biased toward larger particles (Sokolova
et al, 2011). Moreover, a Western blot analysis of the protein
content showed that presumptive exosome markers were abun-
dantly expressed in EVs TEIR isolated from FAP’s supernatant,
including Alix, Hsp70, and to a less extent Flotillin-1 and CD63
(Fig EV1D). EV preparation was cleared from contaminating cell
organelles, as indicated by the absence of Calnexin, an ubiqui-
tously expressed ER protein that was exclusively found in FAP’s
whole-cell fractions (WCL) (Fig EV1D). While these data demon-
strate that FAP-derived EVs display typical features of mammalian
exosomes (EV-TRACK Consortium et al, 2017), in this manuscript
we will continue to refer to these nanoparticles as EVs.
To analyze the capacity of MuSCs to uptake FAP-derived EVs,
we performed a transwell co-culture in which the potential cellular
“source” of EVs—the FAPs—was transfected with the exosomal
marker CD63 fused to GFP prior to transwell co-culture with the
“acceptor” cells—the MuSCs. In this system, detection of GFP into
MuSCs reveals the transfer of CD63-labeled EVs from FAPs to
MuSCs. Figure EV1E shows that GFP signal was detected in FAPs
after transfection with GFP-CD63, as well as in MuSCs co-cultured
with FAPs previously transfected with GFP-CD63. By contrast, no
GFP signal was detected in MuSCs co-cultured with FAPs previously
transfected with a control plasmid (mock) (Fig EV1E). To further
demonstrate the transfer of EVs from FAPs to MuSCs, we incubated
FAPs with the lipidic dye (PKH-67) prior to transwell co-culture with
MuSCs. PKH-67 is incorporated into newly generated EVs; hence, it
can be used to trace EV passage from FAPs to acceptor cells. Indeed,
PKH-67 staining was invariably detected in FAPs exposed to the dye
as well as in recipient co-cultured MuSCs. On the other hand, prior
exposure of FAPs to GW4869 almost completely prevented the
detection of the signal in MuSCs (Fig 1E and F), demonstrating that
FAP-derived EVs are uptaken by MuSCs.
To evaluate whether FAP-derived EVs could deliver regulatory
signals to MuSCs, we incubated MuSCs with EVs isolated from the
supernatant of FAPs from 1.5-month-old mdx mice (CTR). FAP-
derived EVs increased the ability of MuSCs to form multinucleated
myotubes (Fig 1G and H—compare CTR to untreated -MuSCs ()).
To determine whether EVs mediate the ability of HDACi to enhance
FAP’s support to MuSC differentiation, we incubated MuSCs with
EVs that were purified from FAPs of mdx mice exposed for 15 days
to TSA. These EVs further increase the formation of multinucleated
myotubes from MuSCs, as compared to EVs from FAPs of CTR
vehicle-treated mdx (Fig 1G and H—compare TSA to CTR). We next
sought to evaluate whether HDACi could directly promote release of
pro-myogenic EVs, by exposing cultures of FAPs isolated from vehi-
cle-treated mdx mice to TSA (TSA vitro). Exposure of FAPs to TSA
ex vivo led to the release of EVs that promoted MuSC-mediated
formation of multinucleated myotubes to an extent comparable to
that observed with EVs from FAPs isolated from mdx mice treated
in vivo with TSA (Fig 1G and H—compare TSA vitro to untreated).
These results are consistent with data from human DMD patients
shown in Fig 1A and B.
We also evaluated whether HDACi could increase the abundance
of FAP-derived EVs. To this purpose, we exposed the same number
of FAPs isolated from vehicle-treated mice to TSA ex vivo and quan-
tified the number of EVs released in the supernatant. Figure EV1F
and G shows that TSA increased the abundance of EVs in the super-
natant of FAP cultures, as compared to CTR-treated FAPs. As the
supernatant was collected from the same number of cells in each
condition, the increased amounts of EVs did not depend on the
effect of TSA on cell proliferation, but likely reflected an increased
cellular output of EVs.
Enrichment of miR-206 in interstitial EVs correlates with
compensatory regeneration of DMD muscles and treatment
with HDACi
We next investigated whether FAP-derived EVs could be detected in
regenerating muscles, in physiological (acute injury) or pathological
(DMD) conditions. To this purpose, we performed in situ immunoflu-
orescence for CD63, an integral membrane protein enriched in EVs,
on muscle sections from young wild-type (WT) unperturbed (CTR) or
regenerating muscles (4-day post-injury cardiotoxin (CTX) injection)
and from mdx mice at different stages of disease progression (i.e.,
1.5-month-old or 12-month-old mice). We also included sections of
muscles from mdx mice that were exposed or not to the TSA, which
reportedly promotes regeneration in young, but not old, mdx mice
(Mozzetta et al, 2013; Saccone et al, 2014). This analysis revealed
sporadic CD63 signal in WT unperturbed and old mdx muscles, while
a dramatic increase in CD63 signal was observed in regenerating WT
and mdx young muscles (Fig EV2A and B). Interestingly, in all experi-
mental conditions the vast majority of CD63 signal was invariably
detected in the interstitium between regenerating, embryonal eMyHC-
positive fibers, and largely overlapped with interstitial Sca1 signal,
which identifies putative FAP cells. Notably, muscles of mdx young
mice exposed to TSA showed a significant increase in CD63-positive
interstitial signal, as compared to young mdx CTR muscles, with
levels comparable to those observed in regenerating WT muscles
(Fig EV2A and B). By contrast, TSA treatment could not increase the
CD63 signal in the interstitium of muscles from 1-year-old mdx mice,
which have been previously shown to be resistant to the beneficial
effects of HDACi (Mozzetta et al, 2013; Saccone et al, 2014). The
overlap between interstitial CD63 and Sca1 signals, and the close
proximity to eMyHC-positive regenerating myofibers, together with
the differential response of young versus old mdx muscles to HDACi,
suggest that FAP-derived EVs could be implicated in HDACi-mediated
activation of MuSCs to regenerate dystrophic muscles, as previously
indicated by transwell co-culture experiments (Mozzetta et al, 2013).
Previous works have implicated microRNA (miRs), as mediators
of exosome-regulated biological processes (Valadi et al, 2007; Collino
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et al, 2010; Montecalvo et al, 2012; Vlassov et al, 2012; Nakamura
et al, 2015; Fry et al, 2017). To investigate miR contribution to the
ability of FAP-derived EVs to regulate MuSC activity, we first deter-
mined whether FAP-derived EVs could transfer RNA to MuSCs, by
using fluorescent acridine orange (AO)—a specific nucleic acid
staining. AO-labeled FAP-derived EVs were incubated with freshly
isolated MuSCs. Confocal microscopy analysis revealed the presence
of AO-labeled intracellular RNA dots inside recipient MuSCs, both
within and outside the nuclear membrane (Fig EV3A). We have
previously shown that HDACi extensively changes the miR expres-
sion pattern in FAPs from mdx muscles (Saccone et al, 2014).
Therefore, we sought to further investigate the functional impact of
siRNA-mediated blockade of miR biogenesis on muscle regenera-
tion. We evaluated the effect of siRNA-mediated knockdown of
Drosha, the RNA-specific endoribonuclease required for microRNA
biogenesis, on functional interactions between FAPs isolated from
HDACi-treated young mdx mice and MuSCs isolated from control-
treated young mdx mice. siRNA efficiently down-regulated (by
about 60%) Drosha expression in FAPs (Fig 2A) and drastically
reduced the ability of TSA-treated FAPs to enhance MuSC-mediated
formation of multinucleated myotubes in transwell co-culture
(Fig 2B and C). We then determined the identity of the miRs within
FAP-derived EVs, by performing a TaqMan-based miR expression
microarray using EVs purified from the supernatant of FAPs
isolated from mdx mice treated for 15 days with TSA or control
vehicle (CTR). This analysis identified several miRs up-regulated in
EVs from TSA-treated mdx mice. We annotated the top 14 miRs
significantly up-regulated in FAPs from TSA-treated mdx mice
(Figs 2D and EV3B), including miRs that have been previously
implicated in the regulation of skeletal myogenesis (Greco et al,
2009; Liu et al, 2012; Wang et al, 2012; Yamamoto et al, 2012;
Wang, 2013; Guess et al, 2015; Nakamura et al, 2015; Zhao et al,
2016). Ingenuity pathway analysis (IPA) revealed a number of regu-
latory pathways potentially affected by these miRs and implicated
in the control of MuSCs (Fig EV3C). Interestingly, RNA-seq data
generated from MuSCs isolated from mdx mice treated with TSA
versus control vehicle revealed the activation of top pathways (e.g.,
Notch, JAK-STAT) that were also predicted by IPA of the up-regu-
lated miR in EVs from FAPs of TSA-treated mdx mice (Fig EV3D).
Among the TSA-induced EV-miRs, the most up-regulated (17.06-
fold) was the muscle-specific (myomiR) miR-206-3p (herein indi-
cated as miR-206)—a central component of skeletal muscle regener-
ation (Liu et al, 2012; Ma et al, 2015), and HDACi-activated
network in dystrophic muscles (Cacchiarelli et al, 2010; Saccone
et al, 2014). Of note, transgenic overexpression of miR-206 has
been successfully exploited as tool for the treatment of DMD and
other muscular disorders (Williams et al, 2009; Liu et al, 2012; Fry
et al, 2017). Interestingly, in situ hybridization analysis of muscle
biopsies from DMD patients at various ages revealed increased
levels of interstitial miR-206, as compared to control biopsies (from
non-DMD boys) (Fig 2E and F). This analysis also showed a
progressive reduction in interstitial miR-206 along with the disease
progression in coincidence with the exhaustion of the regenerative
activity and the increased severity of fibrosis (Fig 2G–J). The same
pattern could also be observed in mdx mice, in which an abundant
miR-206 signal was detected in the interstitium of tibialis anterior
muscles, overlapping with the immunofluorescence staining of the
FAP’s marker Sca-1 (Fig 3A and B).
We next investigated whether exposure to HDACi could increase
the interstitial amount of intravesicular miR-206 to the levels
observed at earlier stages of disease progression. Treatment of
young mdx mice (1.5 months of age) with TSA, which promotes
regeneration and inhibits fibrosis (Mozzetta et al, 2013; Saccone
et al, 2014), could increase the amount of interstitial miR-206 signal
associated with Sca-1 staining, which was used to identify putative
FAPs (Fig 3A and B). We performed a quantitative assessment (by
qPCR) of EV-miR-206, upon isolation of whole tibialis anterior (TA)
muscles from TSA-treated mdx muscle or control vehicle-treated
mdx mice, followed by mechanic dissociation and EV purification
(Aswad et al, 2014). This procedure enriches for interstitial mate-
rial, as it minimizes EV content in myofibers, and showed a ~5-fold
increase in miR-206 in TSA-treated mdx muscle as compared to
control-treated (Fig 3C).
We then performed in situ hybridization analysis of miR-206
expression and localization in muscle biopsies from DMD patients,
before or after the treatment with Giv. We used muscle sections
available from 18 patients, among the 19 DMD boys enrolled in this
clinical trial, as one dropped off from the trial. In these patients, we
found an increased abundance of miR-206 after Giv treatment
(Fig 3D and E). Of note, the miR-206 signal was detected in the
interstitial space and was almost invariably juxtaposed to CD90
signal, which identifies human FAPs (see merge picture, in which
the IF and hybridization signals are merged, the CD90 signal turns
purple, and the miR-206 signal remains violet). This suggests that
FAPs are the main source of the interstitial miR-206 in DMD
muscles. Consistently, we detected 12- to 16-fold increase in miR-
206 in the EVs from ehFAPs of the biopsies available from our two
DMD patients (Fig 3F).
Interestingly, the miR-206 signal was also detected in myofibers
of regenerating fibers of DMD patients (Fig 2E) and mdx mice
(Fig 3A), but was much attenuated in fibers of DMD patients at late
stage of disease or in control human muscle sections (Figs 2E–G
and 3D). The overall pattern of miR-206 staining inside myofibers
and within the interstitial spaces of regenerating areas of DMD
muscles is consistent with the established role of miR-206 in devel-
opmental and post-natal myogenesis (Yuasa et al, 2008; Cacchiarelli
et al, 2010; Koutsoulidou et al, 2011). Accordingly, increased levels
of miR-206 could be detected in the fibers of mdx mice as well as
DMD patients treated with HDACi (see Fig 3D–F). This is consistent
with the general trend of increased muscle regeneration observed in
DMD patients after 1 year of treatment with Giv (Bettica et al, 2016)
and in mdx mice treated with Giv (Consalvi et al, 2013) or other
HDACi (Minetti et al, 2006; Colussi et al, 2008).
EV-miRs cooperatively promote compensatory regeneration
while reducing fibrosis and inflammation in dystrophic muscles
The enrichment of interstitial EVs with increased amounts of miR-
206 in regenerating DMD muscles suggests that FAP-derived EVs
could transfer miR-206 to MuSC to promote compensatory regenera-
tion. While miR-206 transfer by exosomes from MuSCs to interstitial
fibroblasts has been recently described as a mechanism to hamper
the formation of fibrotic scars during skeletal muscle hypertrophy
(Fry et al, 2017), the reciprocal process—that is, transfer of miR-206
from FAPs to MuSCs—has not been described so far. We therefore
explored the potential transfer of miR-206 from FAPs to MuSCs,
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through EVs, within the context of the mdx muscles. To this
purpose, we quantified MuSC’s uptake of FAP-derived EVs in vivo,
by tracing EVs with PKH-67 labeling. EVs were first purified from
FAPs isolated from mdx mice previously treated with TSA (EVs-
FAPs TSA) and then exposed to PKH-67, prior to their
transplantation into tibialis anterior (TA) muscles. FACS analysis
showed that 17.2% of the whole population of cells isolated from
transplanted TA muscle incorporated PKH-67-labeled EVs (Fig 4A,
left panel). Among them, we found that about 2% of FACS-isolated






Figure 2. Increased amounts of miR-206-3p in DMD muscles associate with muscle regeneration and inversely correlate with disease progression.
A Graph showing the relative expression of Drosha in FAPs after Drosha down-regulation by siRNA (n = 4, biological replicates). Values correspond to the
average  SEM. Star (*) indicates statistical analysis by t-test relative to FAPs TSA treated and transfected with scramble (Scr); **P < 0.01.
B Representative images of myogenic differentiation of MuSCs assessed by immunostaining for MyHC (green). MuSCs were cultured alone () or in transwell co-culture
with FAPs isolated from mdx mice treated either with vehicle (+FAPs CTR) or TSA (0.6 mg/kg/day for 15 days by i.p.) (+FAPs TSA), and transfected with scramble (Scr
siRNA) or Drosha siRNA (Drosha siRNA) prior to co-culture with MuSCs. Scale bar = 50 lm.
C Graph showing the fusion index of MuSCs in the conditions described in (B) (n = 4, biological replicates). Values correspond to the average  SEM. Star (*) indicates
statistical analysis by Tukey’s test relative to MuSCs alone (); *P < 0.05, ****P < 0.0001. Hash (#) indicates statistical analysis by Tukey’s test relative to MuSCs in
co-culture with FAPs CTR transfected with scramble (Scr); ##P < 0.01. Cross (†) means Tukey’s analysis compared to MuSCs in co-culture with FAPs TSA transfected
with scramble (Scr): ††††P < 0.0001. § represents statistical analysis by two-way ANOVA test. §§§P < 0.001.
D Table representing a manually assembled list of microRNAs revealed by microarray analysis and statistically induced by TSA in FAP-derived EVs.
E Representative images of miR-206-3p (violet) immunohistochemistry in vastus medialis bioptic samples of control and DMD patients at different ages: 1 year (n = 2),
4 years (n = 3), and 9 years old (n = 2).
F Graph representing miR-206-3p violet area quantification relative to (E).
G Representative images of immunofluorescence for eMyHC (red) and laminin (green) in conditions described in (E).
H Graph showing the percentage of eMyHC-positive fibers of condition described in (G).
I Representative images of Masson’s trichrome staining in conditions described in (E).
J Graph showing the fibrotic area quantification of conditions described in (I).
Data information: For (E, G, I) Scale bar = 50 lm.
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panel, and Fig 4B). We argue that such a low percentage of
PKH-67-positive MuSCs detected underestimates the actual rate of
MuSC incorporation of FAP-derived EVs, as it is intrinsically
biased by the loss of PKH-67-positive MuSCs, due to the dye
dilution once they proliferate and/or differentiate into large mult-
inucleated myofibers. Consistent with EV-mediated transfer of
miR-206 from FAPs to MuSCs in DMD muscles exposed to
HDACi, MuSCs that incorporated PKH-67-labeled EVs exhibited a
fivefold increase in miR-206 (Fig 4C), further indicating that FAP-
derived EVs significantly increase the intracellular amount of
miR-206 in MuSCs. Furthermore, global inhibition of miR biogen-
esis in FAPs, by Drosha knockdown via RNA interference
(siRNA) prior to EV isolation and injection, was sufficient to
prevent the increase in miR-206 in PKH-67-positive MuSCs
isolated from transplanted muscles (Fig 4C). Likewise, in a paral-
lel experiment, inhibition of EV biogenesis by exposure to
GW4869 abrogated miR-206 transfer from TSA-treated mdx FAPs
to co-cultured MuSC transwell plates (Fig EV4A). When consid-
ered with the previous report from Fry et al (2017), this finding
is consistent with a model of reciprocal exchange of miRs
between FAPs and MuSCs.
We next monitored the effect of EVs-FAP TSA on parameters of
disease progression in mdx mice upon EV transplantation. Since
HDACi exert beneficial effects in mdx mice, by promoting compen-
satory regeneration and by reducing fibrosis and inflammation
(Minetti et al, 2006), we sought to evaluate to what extent these
effects are accounted for by FAP-derived EVs. To this purpose, we
compared the ability of intramuscular (i.m.) injection of EVs puri-
fied from FAPs isolated from mdx mice that were previously treated
with TSA (EVs-FAPs TSA) or vehicle (EVs-FAPs CTR) to stimulate
regeneration, and reduce fibrosis and inflammation. The effect was
compared to systemic exposure to TSA (or vehicle control), which
was administered via daily intraperitoneal injection for 21 days.
Intramuscular injection of EVs was repeated every 7 days for
21 days, in order to allow a direct comparison with the systemic
exposure to TSA. Within this context, we evaluated the specific
contribution of miR-206 to the effects of FAP-derived EVs on mdx
mice, by transfecting with antagomiR-206 FAPs isolated from TSA-
A B C
D E F
Figure 3. HDACi increases miR-206-3p amounts in EVs from DMD FAPs.
A Representative images of Sca-1 (green), laminin (white), DAPI (blue) immunofluorescence, and miR-206-3p (violet) immunohistochemistry on 10 lM sequential cryo-
sections of tibialis anterior (TA) of young mdx mice (CTR) and after TSA treatment (TSA) (0.6 mg/kg/day for 15 days by i.p.) (n = 6). Scale bar = 25 lm.
B Graph showing the quantifications of miR-206-3p violet area relative to conditions indicated in (A). Star (*) indicates t-test analysis **P < 0.01.
C Graph representing the miR-206-3p relative expression in EVs isolated from muscle interstitium of tibialis anterior from wild-type (CTR), mdx young, and old mice
(control (CTR) and TSA treated) (n = 4). Star (*) indicates Tukey’s analysis compared to wild-type mice (CTR), ****P < 0.0001; hash (#) indicates Tukey’s analysis
compared to mdx young CTR, ####P < 0.0001. § represents statistical analysis by ANOVA test. §§§§P < 0.0001.
D Representative images of CD90 (green), DAPI (blue), and miR-206-3p (violet) immunohistochemistry in brachial biceps bioptic samples of DMD patient before (CTR)
and after Givinostat treatment (GIV). Scale bar = 50 lm.
E Graph showing the quantifications of miR-206-3p violet area measured as pixel2/field relative to the experimental points indicated in (D) (n = 18, biological
replicates). Star (*) indicates t-test analysis. **P < 0.01.
F Graph showing the relative expression of miR-206-3p in EVs isolated from a human population of muscle-resident cells enriched in FAPs (ehFAPs) isolated from
biopsies of two DMD patients (DMD-1 and DMD-2) before (CTR) and after (GIV) Givinostat treatment. Two technical replicates are shown.
Data information: Nuclei were counterstained with DAPI (blue). All data for (B, C, and E) correspond to the average  SEM, while the data for (F) correspond to the
average  SD.
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treated mice (EVs-FAPs A-206) prior to EV isolation and injection
into tibialis anterior of mdx mice. As an internal control, we sought
to transfect FAPs with antagomiRs against another HDACi-induced
miR in FAP-derived EVs that has a spectrum of targets non-overlap-
ping with miR-206. To this purpose, we used antagomiRs against
miR-145 (A-145), which displayed a fourfold up-regulation in EVs
derived from FAPs of HDACi-treated mdx mice (Fig 2D) and targets
key mediators of inflammation, such as IL1, IL6, and TGFbeta
signaling (Tahamtan et al, 2018). Transfection of A-206 or A-145 in
FAPs specifically reduced the expression levels of miR-206 or
miR-145, respectively, in FAPs (Fig 4D) as well as in FAP-derived
EVs (Fig 4E). This effect was observed only after miR induction
upon FAP exposure to TSA, but not in untreated FAPs, consistent
with the almost undetectable levels of these miRs in FAPs under
basal conditions.
Mdx muscles injected with EVs-FAP TSA showed an increase in
embryonic-MyHC-positive myofibers (eMyHC) and cross-sectional
area (CSA), comparable to the increase observed in the muscles of
mdx mice following systemic exposure to TSA (Fig 4F–H). Likewise,
EVs-FAPs TSA i.m. injection and systemic delivery of TSA showed a
comparable ability to increase muscle fiber area fraction (MFAF) and
reduce fibrosis (Figs 4I–K and EV4B and C), as well as inflammation,
as determined by reduction of myeloperoxidase (MPO)-positive areas,
in mdx muscles (Fig 4L and M). EVs-FAPs TSA A-206 showed a
reduced ability to stimulate muscle regeneration (Fig 4F–H) and
inhibit fibrosis (Fig 4I–K), but maintained their anti-inflammatory
effects, indicating a selective contribution of miR-206 in promoting
regeneration and reducing fibrosis. By contrast, the anti-inflammatory
effects were lost in EVs-FAPs TSA A-145 (Fig 4L and M). Notably,
EVs-FAPs TSA A-145 also showed reduced pro-myogenic (Fig 4F–H)
and anti-fibrotic effects (Fig 4I–K), as compared to control EVs-FAPs
TSA. It is likely that loss of pro-myogenic and anti-fibrotic activities
in EVs-FAPs TSA A-145 is secondary to the loss of the anti-inflamma-
tory effect, as inflammation typically inhibits myogenic regeneration
and promotes fibrosis. Overall, these data show that the therapeutic
effect exerted by EVs from HDACi-treated FAPs in mdx mice results
from the combinatorial, and often redundant, activities of multiple
intra-EV miRs up-regulated by HDACi.
We also investigated whether the HDACi-mediated up-regulation
of miRs in FAP-derived EVs is direct and cell-specific. We found that
direct exposure of FAPs to TSA ex vivo induced an up-regulation of
the same miRs detected by microarray from EVs isolated from the
supernatant of FAPs derived by TSA-treated mdx mice in vivo (see
Fig 2D), with a comparable magnitude (Fig EV4D). Moreover,
ex vivo exposure to TSA was used to determine whether HDACi-
induced up-regulation of miR-206 in EVs could be observed also in
muscle-derived cell types that typically express miR-206—i.e.,
MuSCs and myotubes. Figure EV4E–H shows that upon ex vivo
exposure to TSA, only FAP-derived EVs exhibited up-regulation of
miR-206, although TSA could increase the transcription of miR-206
in both MuSCs and myotubes. These data indicate that transcrip-
tional up-regulation of miRs by HDACi is not sufficient to increase
their levels in EVs and points to the importance of cell type-specific
post-transcriptional regulation of miR incorporation into EVs.
EVs isolated from FAPs of HDACi-treated dystrophic muscles are
required to promote MuSCs activation and amplification
To gain mechanistic insights into the pro-myogenic activity of EVs
derived from FAPs of HDACi-treated mdx mice, we searched for
putative target genes of miR-206 that matched with down-regulated
genes in our RNA-seq datasets obtained from MuSCs of TSA-treated
mdx mice. A downstream analysis was carried out only for miR-206
targets that have been already annotated or predicted with high con-
fidence. Ingenuity pathway analysis (IPA) revealed a potential effect
of miR-206 on various signaling pathways involved in muscle devel-
opment and disease, including Utrophin (UTRN), Pax7, and Notch3
(Rosenberg et al, 2006; Chen et al, 2010; Gagan et al, 2012; Amir-
ouche et al, 2014) (Fig EV5A). We decided to focus on miR-206
regulation of Notch3, as negative regulator of MuSC differentiation,
◀ Figure 4. FAP-derived EVs promote regeneration and inhibit fibrosis and inflammation in dystrophic muscles of mdx mice.A Flow cytometric analysis of mdx muscles injected with PKH67-labeled EVs isolated from FAPs of 1.5-month-old mdx mice exposed to TSA. The left panel shows the
percentage of PKH-67-positive cells in whole muscle. The right panel shows the percentage of the PKH-67-positive MuSCs.
B Representative images of PKH-67 (green) and DAPI (blue) staining in MuSCs freshly isolated from muscles previously injected with PKH67-labeled EVs. Scale
bar = 25 lm.
C Graph showing the relative expression of miR-206-3p in MuSCs isolated as described in (A, B) and in MuSCs from muscles injected with PKH67-labeled EVs isolated
from FAPs of 1.5-month-old mdx mice exposed to TSA, and then transfected or not with Drosha siRNA (siRNA Drosha) (n = 4). Star (*) means significance relative
to MuSCs that not uptake PKH67-labeled EVs, **P < 0.01. Hash (#) means significance compared to MuSCs that uptake EVs-FAPs TSA, ##P < 0.01. § indicates ANOVA,
§§P < 0.01.
D Graph showing the expression levels of miR-206-3p and miR-145-5p in FAPs treated or not with TSA after antagomiR treatment (n = 3, biological replicates). Star
(*) indicates statistical analysis by t-test relative to FAPs (); *P < 0.05, **P < 0.01.
E Graph showing the expression levels of miR-206-3p and miR-145-5p in FAP-derived EVs treated or not with TSA after antagomiR treatment (n = 3, biological
replicates). Star (*) indicates statistical analysis by t-test relative to FAPs (); *P < 0.05.
F–M Stainings and relative measurements on tibialis anterior muscle transversal sections of 1.5-month-old mdx mice treated daily for 21 days with intraperitoneal
injection of vehicle (CTR) or TSA, or once a week with intramuscular injections (tibialis anterior) of EVs derived from FAPs (EVs-FAPs) exposed or not to TSA in vivo
(EVs-FAPs CTR (), EVs-FAPs TSA ()) EVs derived from FAP control transfected with the antagomiR-206 (EVs-FAPs CTR A-206) and of EVs-FAPs TSA transfected
with antagomiR-206 and antagomiR-145 (EVs-FAPs TSA A-206, EVs-FAPs TSA A-145). EVs were injected every 7 days and sacrificed after 21 days of treatment
(n = 5 for CTR, TSA EVs-FAPs CTR, and EVs-FAPs TSA, while for antagomiRs, n = 3, biological replicates). (F) Representative images of immunofluorescence for
embryonic myosin heavy chain (eMyHC—red) and laminin (Lam—cyan) stainings. Scale bar = 50 lm. (G) Graph showing the quantification of cross-sectional area
(CSA). (H) Graph showing the quantification of muscle regeneration (eMyHC). (I) Representative images of Masson’s trichrome staining. Scale bar = 50 lm. (J)
Graph showing the quantifications of muscle fiber area fraction (MFAF). (K) Graph showing the quantifications of fibrotic area. (L) Representative images of
myeloperoxidase staining (MPO—red). Scale bar = 50 lm. (M) Graph showing the quantifications of inflammation (MPO).
Data information: Nuclei were counterstained with DAPI (blue). Statistical analysis by ANOVA and Tukey’s test. All data correspond to the average  SEM. In (A-H), star (*)
means significance compared to CTR, *P < 0.05, **P < 0.01; ***P < 0.001; ***P < 0.0001, while hash (#) means significance compared to EVs-FAPs CTR (), #P < 0.05,
##P < 0.01, and (†) means significance to EVs-FAPs TSA (), †P < 0.05, ††P < 0.01, ††††P < 0.0001. § indicates significance by ANOVA test; §§§P < 0.001; §§§§P < 0.0001.
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because previous work demonstrated that miR-206 down-regulation
of Notch3 promotes MuSC differentiation (Gagan et al, 2012). We
therefore purified EVs from FAPs isolated from TSA- or control (ve-
hicle)-treated 1.5-month-old mdx mice for 21 days and evaluated
their effect on MuSC ability to form myotubes, while monitoring the
expression levels of Notch3 and Notch1. EVs from FAPs of TSA-
treated mdx mice increased MuSC ability to form multinucleated
myotubes, and this effect was abrogated by antagomiR-mediated
depletion of miR-206 in FAP-derived EVs (Fig 5A and B). In keeping
with the opposite roles of Notch members in MuSC activation (Kita-
moto & Hanaoka, 2010), we reasoned that selective down-regulation
of Notch3 in MuSCs upon incorporation of FAP-derived EVs could
promote MuSC activation and self-renewal. Indeed, while Notch3
and Notch1 transcripts were both reduced in MuSCs isolated from
mdx mice treated with TSA, we observed a selective down-
regulation of Notch3 transcripts in MuSCs isolated from control-
treated mice and cultured with EVs derived from FAPs of
TSA-treated mdx mice (Fig 5C and D).
We next evaluated the effect of EVs derived from FAPs of
HDACi-treated or control-treated mdx mice on MuSCs within single
fibers isolated from WT mice. Freshly isolated single muscle fibers
from tibialis anterior, extensor digitorum longus, gastrocnemius and
soleus of C57BL/6J mice were incubated with FAP-derived EVs or
whole conditioned media, and their effect on MuSCs was evaluated
by monitoring the expression of Pax7, MyoD, and DNA synthesis
(EdU incorporation). In this experimental setting, the uptake of
FAP-derived EVs by MuSCs from single fibers was first confirmed
by staining of lipidic dye PKH-67 used to label purified vesicles
(Fig 5E). Figure 5F and G shows that the whole supernatant derived
from FAPs of control-treated mdx mice increased the number of
Pax7+/MyoD+ MuSCs that showed enhanced DNA synthesis
(Edu+) and could be therefore considered activated MuSCs (Zammit
et al, 2004). Indeed, nearly 100% of the EdU+ nuclei were also
Pax7+/MyoD+. Moreover, the whole supernatant derived from
FAPs of TSA-treated mdx mice could further augment this effect.
While a drastic reduction in the number of quiescent (Pax7+
MyoD) and differentiation-committed MuSCs (Pax7 MyoD+)
was observed upon incubation with the whole supernatant of
FAPs isolated from control-treated mdx mice and pre-exposed to
GW4869, the number of Pax7+/MyoD+ MuSCs with high DNA
synthesis (Edu+) was not altered in these conditions (Fig 5F and
G). By contrast, GW4869 treatment of FAPs from TSA-treated mdx
mice drastically reduced the ability of the whole supernatant to
increase all MuSC populations as well as their proliferation (Fig 5F
and G). These data indicate that the ability of FAPs from HDACi-
treated mdx mice to promote expansion of MuSCs depends on
EVs. Indeed, only EVs from FAPs of TSA-treated (but not from
control-treated) mdx mice increased the number of Pax7+/MyoD+
MuSCs (Fig 5F and G). We then investigated the relative contribu-
tion of miR-206 in mediating the ability of EVs isolated from FAPs
of TSA-treated mdx mice to support MuSC activation, expansion,
and differentiation. AntagomiR-mediated depletion of miR-206
drastically reduced the ability of EVs isolated from FAPs of TSA-
treated mice to support the expansion of Pax7+/MyoD+ as well
as Pax7/MyoD+ MuSCs (Fig 5F and G). This result demonstrates
the essential function of miR-206 in mediating HDACi ability to
promote functional interactions between dystrophic FAPs and
MuSCs.
Discussion
Defining the identity of extracellular mediators that coordinate the
activities of the cellular components of the MuSC niche is a major
challenge in regenerative medicine, as it might inspire selective
interventions toward promoting compensatory regeneration of
diseased muscles, while eliminating the most unfavorable outcome
of disease progression, such as maladaptive repair by deposition of
▸Figure 5. EVs from FAPs in vivo exposed to TSA promote MuSC differentiation, expansion, and asymmetric division.A Representative images of myogenic differentiation of MuSCs assessed by immunostaining for MyHC (green). Nuclei were counterstained with DAPI (blue). MuSCs
were cultured alone () or with EVs (EVs-FAPs) isolated from FAPs in vivo exposed or not to TSA (CTR and TSA) and transfected or not with antagomiR-206 (() and
A-206). (n = 7 for all samples, but antagomiR’s samples n = 3, biological replicates). Scale bar = 50 lm.
B Graph showing the fusion index of MuSCs in the condition described in (A). Star (*) indicates statistical analysis by Tukey’s test relative to MuSCs cultured alone (),
*P < 0.05, ****P > 0.0001; hash (#) means significance compared to EVs-FAPs CTR (), ###P < 0.001; and (†) means significance to EVs-FAPs TSA (), ††††P < 0.0001.
§ indicates significance by ANOVA test; §§§§P > 0.0001.
C Graph relative to Notch3 expression in MuSCs isolated from 1.5-month-old mdx mice treated with either vehicle (CTR) or TSA (TSA), and in EVs derived from FAPs
(EVs-FAPs) isolated from 1.5-month-old mdx mice treated with either vehicle (CTR) or TSA (TSA) (n = 3). Star (*) indicates statistical analysis by Tukey’s test relative to
mdx vehicle-treated mdx mice (CTR); *P < 0.05. Hash (#) means significance compared to EVs-FAPs CTR, ##P < 0.01. § indicates significance by ANOVA test;
§§P > 0.01.
D Graph relative to Notch1 expression in MuSCs isolated from 1.5-month-old mdx mice treated with either vehicle (CTR) or TSA (TSA), and in EVs derived from FAPs
(EVs-FAPs) isolated from 1.5-month-old mdx mice treated with either vehicle (CTR) or TSA (TSA) (n = 3). Star (*) indicates statistical analysis by Tukey’s test relative to
mdx vehicle-treated mdx mice (CTR); *P < 0.05. § indicates significance by ANOVA test; §§P>0.01.
E Representative images showing myofibers cultured alone (CTR) or with extracellular vesicles isolated from FAPs (EVs-FAPs) and stained with PKH-67 (green) and
MyoD (red). Nuclei were counterstained with DAPI (blue). Arrows represent nuclei positive for both PKH-67 and MyoD. Scale bar = 25 lm.
F From left to right: representative images of myofibers cultured for 24 h alone () or with conditioned media of FAPs that were previously exposed or not to TSA and
GW4869 (MEDIA-FAPs) or extracellular vesicles (EVs-FAPs) collected from FAPs exposed or not to TSA in vivo (CTR and TSA) and transfected with antagomiR-206 (TSA
A-206). Myofibers have been stained for EdU (cyan) and immunofluorescence with Pax7 (green) and MyoD (red). Nuclei were counterstained with DAPI (blue). (n = 3).
Scale bar = 25 lm.
G Graph showing the average of nuclei positive for Pax7 (green) and MyoD (red) in the conditions indicated in (F). Star (*) indicates statistical analysis by Tukey’s test
relative to myofibers cultured alone (), (n = 3, biological replicates). *P < 0.05, **P < 0.01; ***P < 0.001; ***P < 0.0001; hash (#) means significance compared to
MEDIA-FAPs CTR, #P < 0.05; (†) means significance to EVs-FAPs CTR, †P < 0.05, while ¶ means significance compared to EVs-FAPs TSA, ¶¶¶¶P < 0.0001. § means
significance by ANOVA test; §§P < 0.01.
Data information: All data correspond to the average  SEM.
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fibrotic and adipose tissue that typically compromises contractile
activity and regenerative potential of muscles.
While a variety of soluble factors, including inflammatory cytoki-
nes and growth factors, have been implicated as mediators of recip-
rocal functional interactions between the major cellular components
of the muscle stem cell niche, EVs are emerging as powerful tool to
transfer biochemical and genomic information from one cell type to
another (Lee et al, 2012; Iraci et al, 2016; Kalluri & LeBleu, 2020).
Indeed, by virtue of their content in proteins and nucleic acids, EVs
enable the cross-activation of biological process between neighbor
cells that account for their functional interactions. As such, the qual-
itative and quantitative control of proteins and RNA content appears
as two major determinants of EV biological activity. Likewise, the
direction of cell-to-cell transmission of EVs influences the final
biological outcome of EV activity. Our finding that a subset of miRs
up-regulated in EVs from FAPs of dystrophic muscles exposed to
HDACi promote MuSC activity and compensatory regeneration of
DMD muscles indicates that the biological activity of EVs is in prin-
ciple pharmacologically tunable for therapeutic purposes.
A seminal discovery from Peterson’s laboratory has recently
revealed that MuSC-derived exosomes containing miR-206 are
required to eliminate fibrosis during muscle hypertrophy (Fry et al,
2017). Moreover, myofiber-derived exosomes have been reported to
promote skeletal myogenesis (Choi et al, 2016). The pro-regenera-
tive and anti-fibrotic activities of miR-206 have been largely docu-
mented by previous studies (Ma et al, 2015). However, while these
studies invariably indicated skeletal myofibers and MuSCs as only
source of miR-206, our previous studies have revealed that FAPs
from dystrophic muscles turn into an alternative cellular source of
miR-206, once exposed to HDACi, and identified a miR-206-directed
network that represses the adipogenic and fibrotic program in FAPs
of dystrophic muscles (Saccone et al, 2014).
Our study provides the first evidence that FAP-derived EVs medi-
ate functional interactions with MuSCs and that EV-miR content
could be pharmacologically modified by epigenetic drugs (e.g., by
HDACi) for therapeutic purposes in both human DMD patients and
mouse model of DMD. In this regard, we note that the beneficial
effects of focal delivery of EVs-FAPs TSA by i.m. injection were
comparable or even greater than those observed upon systemic
delivery of TSA (see Fig 4).
Our results further extend our knowledge on the role of miR-206
expressed in FAPs of DMD muscles exposed to HDACi (Saccone
et al, 2014), by showing that it is incorporated into EVs, which are
released in the regenerative environment and are uptaken by
MuSCs. Our data show that mdx MuSCs that incorporated EVs
released from HDACi-treated FAPs exhibited a fivefold increase in
miR-206. In this regard, while the levels of miR-206 are significantly
lower in FAPs and FAP-EVs, as compared to MuSCs, repeated
uptake of large amounts of FAP-derived EVs overtime can lead to an
overall increase in miR levels, as observed in MuSCs from DMD
muscles exposed to HDACi. This is consistent with the very high
numeric ratio between FAPs and MuSCs during muscle regenera-
tion, whereby multiple FAPs can feed one MuSC. Furthermore, the
output of EV release from FAPs could also account for repeated
events of EV transfer from FAPs to MuSCs, to further increase the
amount of miR that can be potentially be transferred from FAPs to
MuSCs. We speculate that an increased exchange of EVs from FAPs
to MuSCs could support the high regeneration demand imposed to
MuSCs of DMD muscles subjected to repeated cycles of degenera-
tion/regeneration. In this condition, pharmacological modulation of
EV content (as obtained by exposure to HDACi) could exert potent
biological effects, as observed in our study.
Although we have detected a low percentage of MuSCs (2%) that
incorporated FAP-derived EVs upon intramuscular injection, we
argue that this low number might underestimate the actual rate of
EV incorporation by MuSCs in DMD muscles, due to the progressive
dilution of the EV tracing signal (e.g., PKH-67) upon mitotic division
and/or differentiation into myofibers of MuSCs—two events that
occur at high frequency at early stages of DMD progression. While
these scenarios remain purely speculative at this stage, the advent
of more accurate methods of EV tracing in recipient cells will allow
to clarify this important issue in future studies.
Based on our data, we propose that additional amounts of miR-
206 levels provided by EVs from HDACi-treated FAPs might correct
the dysfunctional phenotype of MuSCs from DMD muscles. The
recent finding that dystrophin-deficient MuSCs lose their ability to
divide asymmetrically and regenerate DMD muscles (Dumont et al,
2015a; Chang et al, 2016) indicates that additional events down-
stream of dystrophin can be dysregulated in DMD MuSCs. Among
them, repression of miR-206 expression has been previously
reported in DMD MuSCs (Cacchiarelli et al, 2010) and could be
compensated by FAP-derived EVs-miR-206 in order to restore MuSC
ability to regenerate dystrophic muscles.
Seemingly, conflicting data have been reported regarding the role
of miR-206 in the pathogenesis of DMD, with beneficial effects
observed in mdx mice upon transgenic miR-206 overexpression (Liu
et al, 2012), while genetic ablation of the miR-206/133b cluster
could not worsen the pathology in mdx mice (Boettger et al, 2014).
These data indicate that although miR-206 is dispensable for the
compensatory regeneration observed in mdx mice, increased
amounts of intramuscular miR-206 might exert therapeutic effects
by enhancing the regeneration potential of mdx muscles.
Of note, a multitude of miRs, in addition to miR-206, were found to
be up-regulated in EVs derived from DMD FAPs, upon the exposure to
HDACi, and antagomiR-mediated neutralization of one of these addi-
tional miR (e.g., miR-145) indicates that the cooperative action of
these miRs accounts for the net biological effect of EVs from HDACi-
treated DMD FAPs. Further studies should elucidate the mechanism
by which HDACi regulates EV biogenesis and content, both the tran-
scriptional and post-transcriptional levels, and will define the potential
for further development of interventions based on FAP-derived extra-
cellular vesicles as potential selective treatment for DMD.
Finally, our study suggests that specific interstitial amount of
intra-EV miRs (i.e., miR-206) could be exploited as biomarker of
disease progression and/or therapeutic response to interventions
that counter DMD progression.
Materials and Methods
Experimental model and subject details
Animals
Mice were bred, handled, and maintained according to the standard
animal facility procedures, and all experimental protocols were
approved by the internal Animal Research Ethical Committee
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according to the Italian Ministry of Health and the ethic committee
of the Fondazione Santa Lucia (FSL) approved protocols.
C57BL/6 mice were provided by the Core Structure of the EMMA
(European Mouse Mutant Archive, Monterotondo, Rome); C57BL/6
mdx mice were purchased from Jackson Laboratories. Note that the
term of “young” is referred to C57BL/6/mdx mice of 6/8 weeks old,
which includes the temporal frame in which the beneficial effects of
HDACi are restricted (Mozzetta et al, 2013; Saccone et al, 2014),
while the term of “old” is referred to C57BL/6/mdx mice of 1 year
old.
Human samples
Human biopsies were collected with informed patients’ and parental
consent in compliance with Good Clinical Practice and the Declara-
tion of Helsinki and provided by Dr. Bertini and Dr. D’Amico (Ospe-
dale Bambino Gesù, Rome). We used 10-lm transversal sections
isolated for research purposes from vastus medialis of DMD boys, at
different ages: 1 year old (n = 2), 4 years old (n = 3), and 9 years
old (n = 2), and we compared with a vastus medialis section of
control (non-DMD) samples.
Human bioptic samples obtained from brachial biceps from DMD
boys participating to the clinical trial with Giv (www.ClinicalTria
ls.gov; EudraCT Number: 2012-002566-12; Sponsor Protocol
Number: DSC/11/2357/43) were provided by Italfarmaco S.p.A.
(Milan) (23). The phase II study was approved by the local ethics
committees and authorized by the Competent Authority of Italy.
Parents of the participants provided informed written consent and
each subject provided written assent before participation.
Mice and animal procedures
Animals were used at the specified age and treated with daily
intraperitoneal injections of Trichostatin A (TSA) (0.6 mg/kg/day
for 15 days to obtain FAPs for co-culture and for EV isolation or
21 days for the transplant experiments; #T8552, Sigma) and
dissolved in DMSO solution or in DMSO alone as vehicle control
(CTR). Muscle injury was performed by intramuscular injection in
tibialis anterior (TA) of Cardiotoxin (CTX) (10 lM, 10 mg/ml)
(#L8102, Latoxan Valence, France, http://latoxan.com), 4 days
before mouse sacrifice.
FAP-derived EVs at a final concentration of 10 lg in 20 ll of PBS
1× (0.5 lg/ll) (#14190-1444, Gibco by Life Technologies) and its
vehicle of control (20 ll PBS 1×) were injected 3 times in left TA of
young C57BL/6/mdx mice: every 7 for 21 days.
Histology and in situ hybridization
The tibialis anterior muscles were snap-frozen in liquid
nitrogen-cooled isopentane and then cut transversally with a
thickness of 7 lm.
For Masson’s trichrome staining to analyze fibrotic tissue,
muscle cryo-sections were fixed for 200 at 56°C in Bouin’s solution
(#HT10132, Sigma) and then stained in Working Weigert’s Iron
Hematoxylin solution for 5 min (#HT1079, Sigma), washed in
running tap water for 5 min, and stained in Biebrich scarlet-acid
fuchsin for 5 min (#HT151, Sigma). Sections were rinsed in de-
ionized water and re-fixed in freshly made phosphomolybdic/phos-
photungstic/dH2O (1:1:2) acid solution for 8 min (#HT153, #HT152,
Sigma), and then, they were stained in Aniline Blue solution for
5 min (#HT154, Sigma) and in acetic acid 1% for 2 min (#27221,
Sigma). The slides were dehydrated in ethanol (#02860, Sigma) and
xylene (#X1040, Sigma) and mounted with EUKITT (#03989,
Sigma), and then visualized using a Nikon Eclipse 90i; collagen
fibers are stained in blue, the nuclei are stained in black, and the
muscle tissue is stained in red. miRNA in situ hybridization was
performed in formaldehyde- and carbodiimide (EDC)-fixed TA cryo-
sections (0.16 M 90 min at RT, #25952-53-8, Merck KGaA). After
washing with 0.2% glycine (#G8898, Sigma) and TBS, cryo-sections
were acetylated using 0.1 M triethanolamine and 0.25% acetic
anhydride for 25 min at RT (respectively, #90275, #A6404, Sigma).
These steps are followed by a pre-hybridization using 2× SSC, 25%
formamide (#F9037, Sigma), and 0.2% Triton (#X100, Sigma) for
30 min at RT, and by the overnight hybridization at 4°C with the
hsa-miR-206 probe (10 pmol, #18100-01, Exiqon) dissolved in a
solution of 50% formamide, 250 lg/ml tRNA (#R1753, Sigma),
200 lg/ml SSDNA (#D7656, Sigma), 10% dextran sulfate (#D8906,
Sigma), and 2× SSC. The hybridization was followed by specific
washes with SSC to eliminate non-specific binding of probe (5× SSC
5 min at RT, 1× SSC 15 min at 45°C, 2% BSA in 0.2× SSC 15 min at
4°C, 2× SSC 5 min at RT, TN buffer 10 min at RT, and TNT buffer
150 at RT) and by the incubation of cryo-section using anti-
digoxigenin-ap Fab fragments (1/100, #11093274910, Roche)
dissolved in TN buffer for 2 h at RT. To reveal the miRNA probe-
specific binding, cryo-sections, covered from light, were incubating
overnight at 4°C with 0.375 mg/ml of NBT and 0.188 mg/ml BCIP
dissolved in a solution of TMN buffer (respectively, #11383213001
and #11383221001, Roche).
TN buffer is composed of 0.1 M Tris–HCl (#T1503, Sigma) and
0.15 M NaCl (#S3014, Sigma) at pH 7.5; TNT buffer is TN buffer
with 0.1% Tween (#P1379, Sigma), while TMN buffer is composed
of 0.1 M Tris–HCl, 0.005M MgCl2 (#M8366, Sigma), 0.5 M NaCl,
and 2 mM of Levamisole (#L9756, Sigma).
Isolation of FAPs and satellite cells (MuSCs)
hMuSCs were isolated from human biopsies as CD31 neg/CD45 neg/
CD11b neg (Lin-)/CD56 pos cells and ehFAPs as Lin-/CD56 neg cells.
Live/dead staining was used to check cell vitality.
FAP cells were isolated from mdx mice as TER119neg/CD45neg/
CD31neg/alpha7INTEGRINneg/SCA-1pos cells; MuSCs were isolated
from mdx mice as TER119neg/CD45neg/CD31neg/alpha7INTE-
GRINpos/SCA-1neg cells (Mozzetta et al, 2013).
Briefly, human biopsies or hind limb muscles for each mouse
were minced and put into a 15-ml tube containing 4 ml of HBSS
(#24020-091, Gibco), BSA (0.2%, #A7030, Sigma), and 10 units/ml
penicillin and 10 lg/ml streptomycin (P/S), 2 mg/ml collagenase A
(#10103586001, Roche), 2.4 U/ml dispase II (#04942078001,
Roche), and 10 mg/ml DNase I (#11284932001, Roche) at 37°C
under gentle agitation for 1 h and 30 min. The supernatants were
filtered through a 100-lm, 70-lm, and 40-lm cell strainers (#08-
771-19, #08-771-2, #08-771-1, BD Falcon). Cells were spun for
15 min at 300 g at 4°C; the pellets were resuspended in 0.5 ml of
HBSS 1× containing DNase I and incubated with antibodies on ice
for 30 min. The following antibodies were used: CD45-eFluor 450
(1/50, #48-0451-82, leukocyte common antigen, Ly-5, eBioscience),
CD31-eFluor 450 (1/50, PECAM-1, #48-0311-82, eBioscience),
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TER-119-eFluor 450 (1/50, clone TER-119, #48-5921-82, eBio-
science), Sca1-FITC (1/50, Ly-6A/E FITC, clone D7, #11-5981-82,
eBioscience), Itga7-649 (1/500, AbLab #67-0010-01), anti-human
CD31-FITC (#21270313, ImmunoTools), anti-human CD45-FITC
(#130-080-202, Miltenyi Biotec), anti-human CD11b-FITC (#130-
081-201, Miltenyi Biotec), and anti-human CD56-PE (#12-0567-42,
eBioscience). HBSS was added, and cells were spun for 5 min at
300 g at 4°C to stop the reaction. The cells were resuspended in
HBSS containing 1% DNase I and were isolated based on size, gran-
ulosity, and fluorophore levels using a FACS MoFlo Astrios EQ High
Speed Cell Sorter (Beckman Coulter) and analyzed using FlowJo.
Cell culture
MuSCs and FAPs, either from human or mouse samples, were
cultured after sorting directly in culture media: for MuSCs: 20% FBS
(#16000044, Gibco), 10% HS (#26050-070, Gibco), 1% penicillin–
streptomycin (#15140, Gibco), 1% Chicken Embryo Extract (CEE,
#CE-650-F, Seralab) in DMEM + Pyruvate (#41966, Gibco), and for
FAPs: BIO-AMF-2 (Biological Industries). MuSCs were plated at low
density on regular cell culture dishes coated with gelatin 0.1%
(#07903, Stemcell).
FAP cells were cultured in BIO-AMF-2 at high density (200,000
cells in 10-cm-well plate) for extracellular vesicle isolation and at
low density (40,000 or 10,000 cells, respectively, in 6- or 24-well
dishes) for co-culture experiments.
For HDACi in vitro treatment, cells were exposed to TSA (50 nM)
for 12 h before EV isolation.
To isolate EVs, cells reached 80–90% of confluence; then, the
medium was replaced with serum-free DMEM (+ pyruvate + 4.5 g/l
glucose + glutamate) for 24 h.
Transwell co-culture experiments
MuSCs and FAP cells, both from human or mouse samples, were co-
cultured by using inserts with 1.0-lm porous membrane (#353102,
#353104, Falcon) to avoid direct contact between populations.
Freshly sorted MuSCs were plated in the bottom of the plate,
while FAP cells were plated on the upper insert.
Single-fiber isolation and culture
Single fibers were isolated from tibialis anterior, extensor digitorum
longus, gastrocnemius, and soleus muscles of C57BL/6J-WT mice
(Tucciarone et al, 2018) and cultured in proliferating medium
(GM1: DMEM + pyruvate + 4.5 g/l glucose + glutamate, 10% horse
serum (HS), 0.5% Chicken Embryo Extract) for 24 h, and then
exposed for the next 24 h to GM1 conditioned media derived from
culture of FAPs (MEDIA-FAPs) isolated from young mdx mouse
treated for 15 days with vehicle (CTR) or mdx mice treated with
TSA (TSA) or media isolated from FAPs CTR and TSA pre-treated
with the GW4869 to inhibit exosome biogenesis. In a parallel, inde-
pendent experiment, single fibers were exposed to EVs (EVs-FAPs)
purified from MEDIA-FAPs and added to GM1 for 24 h.
Cell treatments
The transfection of FAPs with pCT-CD63-GFP plasmid (#CYTO120-
PA-1, System Biosciences) and with a GFP-control vector (mock) in
cell culture inserts was accomplished using Lipofectamine 2000
(#12566014, Thermo Fisher Scientific) 6 h before MuSC co-culture.
Transwell co-cultures were maintained in GM2 medium for 24 h
and then harvested for GFP analyses.
To decrease FAP-EV release, GW4869 (10 lM, #D1692, Sigma)
was added to FAP culture 30 min before the co-culture setting with
MuSCs. To wash away any residual trace of GW4869, FAP media
was refreshed right before co-culture.
For siRNA or antagomiR transfection, FAPs isolated from mdx
mice were transfected with siRNA for Drosha, antagomiR-206
(mmu-miR-206-3p miRCURY LNATM microRNA inhibitor, Exiqon),
and antagomiR-145 (mmu-miR-145a-5p miRCURY LNATM microRNA
inhibitor, Exiqon) using DharmaFECT 3.0 (#T2003-03, Thermo
Fisher Scientific) according to the manufacturer’s instructions; after
6 h, the medium was replaced with DMEM serum-free for 24 h
before exosome isolation and purification.
To stain FAP-derived EVs, FAP cells were incubated with the
lipidic dye PKH-67 (#P7333, Sigma) according to the manufacturer’s
instructions prior to transwell co-culture with MuSCs.
In ex vivo experiments, FAP-derived EVs (10 lg) isolated by
TEIR were put in culture with MuSCs or with myofibers in the cell
culture media.
For the in vitro treatment with TSA, cells were exposed to TSA
(50 nM) for 12 h.
Immunofluorescence
For immunofluorescence analysis, cryo-sections and cells were fixed
in 4% PFA for 10 min and permeabilized with 100% cold acetone
(#32201, Sigma) for 6 min at 20°C or 100% cold methanol
(#32213, Sigma) for 6 min at 20° or with 0.25% Triton for 15 min
at RT. Muscle sections were blocked for 1 h with a solution contain-
ing 4% BSA (#A7030, Sigma) in PBS. The primary antibody incuba-
tion was performed O.N. at 4°C, and then, the antibody binding
specificity was revealed using secondary antibodies coupled to
Alexa Fluor 488, 594, or 647 (Invitrogen). Sections were incubated
with DAPI in PBS for 5 min for nuclear staining, washed in PBS,
and mounted with glycerol 3:1 in PBS. The primary antibodies used
for immunofluorescences are as follows: rabbit anti-Laminin (1/400,
#L9393, Sigma); rat anti-SCA1 (1/100, #11-5981-82 Ly-6A/E FITC,
eBioscience); mouse anti-eMyHC (1/20, #F1.652, Developmental
Studies Hybridoma Bank, DSHB, http://dshb.biology.uiowa.edu/F1-
652); mouse anti-MF20 (1:20, Developmental Studies Hybridoma
Bank, DSHB, http://dshb.biology.uiowa.edu/MF-20); mouse anti-
PAX7 (1/10, Developmental Studies Hybridoma Bank, DSHB,
http://dshb.biology.uiowa.edu/PAX7); rabbit anti-MyoD-318
(#SC760, Santa Cruz Biotechnology); EDU (#C10350, Invitrogen);
rat anti-CD63 PE (#143904, clone NUG-2, BioLegend) and myeloper-
oxidase/MPO (1/100 #MAB3174, R&D), and anti-human C90 (Thy-
1) (1:150 #14090980, eBioscience).
Cytohistochemistry
To stain lipids in ehFAPS, cells were fixed in 4% PFA for 10 min
and then washed with 60% isopropanol, stained with Oil Red O in
60% isopropanol, and rinsed with water (Mozzetta et al, 2013).
RNA preparation and RT–qPCR
Total RNA from cell cultures and from plasma was extracted with
TRIzol reagent (#T9424, Sigma), and 0.5–1 lg was retro-transcribed
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using the TaqMan reverse transcription kit (Applied Biosystems).
Real-time qPCR was performed using primers (MmDrosha Fw:50
TGCAAGGCAATACGTGTCATAG 30; MmDrosha Rev:50 TGAAAGC
TGGTGCTGAAGGT 30; MmNotch1 Fw: 50TGAGACTGCCAAAG
TGTTGC 30; MmNotch1 Rev: 50 GTGGGAGACAGAGTGGGTGT 30;
MmNotch3 Fw:50 GTCCAGAGGCCAAGAGACTG 30; MmNotch3
Rev:50 CAGAAGGAGGCCAGCATAAG 30; MmCol1a1 Fw:50 CCT
CAGGGTATTGCTGGACA 30; MmCol1a1 Rev: 50 GAAGGACCT
TGTTTGCCAGG 30; MmCol3a1 Fw:50 CCCAACCCAGAGATCCCATT
30; MmCol3a1 Rev:50 GGTCACCATTTCTCCCAGGA 30; MmFibro-




EVs were isolated from FAP serum-free cell culture medium in
parallel by ultracentrifugation (UC) and with Total Exosome Isola-
tion Reagent (TEIR) (#4478359, Invitrogen by Thermo Fisher Scien-
tific) according to the manufacturer’s instructions. EVs were
isolated by UC and quantified according to a previously published
method (Théry et al, 2006; Van Deun et al, 2014). This isolation
method included a penultimate centrifugation step in Eppendorf
polypropylene conical tubes (10,000 g for 30 min at 4°C, in Eppen-
dorf rotor F-34-6-38) that allowed the removal/isolation of larger
microvesicles. Subsequently, nano-sized EVs, comprised mainly of
exosomes, were pelleted in Beckman Coulter polypropylene open
top tubes (110,000 g for 70 min at 4°C, in Beckman rotor SW28).
After washing, the pellet was resuspended either in RIPA buffer or
in PBS, for further immunoblotting or biophysics and molecular
analyses, respectively. To estimate the amount of secreted vesicles,
we quantified and compared the total protein content of the vesicle
lysates using the BCA assay.
EVs were purified from tibialis anterior gently dissociated in
serum-free DMEM (24 h). Cell debris and organelles were eliminated
by centrifugation at 2,000 g for 20 min, and EVs were isolated using
TEIR. For their characterization by electron microscopy, EVs were
isolated using TEIR and then purified using exosome spin columns
(MW3000, Invitrogen) following the manufacturer’s protocol.
EVs characterization
EV size distribution was determined by dynamic light scattering
(DLS) measurements. Collected EV samples were diluted to a final
concentration of 15 lg/ml total protein content in order to avoid
multiple scattering artifacts. Static and dynamic light scattering
measurements were performed at 20°C by using a Brookhaven
Instruments BI-9000 correlator and a solid-state laser tuned at
k0 = 532 nm. Scattered intensity autocorrelation functions g2(t)
have been analyzed by using multiple gamma functions for the dif-
fusion coefficient and therefore by using the classic Stokes–Einstein
relation to determine the size distribution P(D) of vesicles, where
the size parameter D is actually the hydrodynamic radius of dif-
fusing vesicles (Noto et al, 2012).
EV morphology was examined for scanning electron microscopy
analysis. EVs isolated and purified from FAPs by TEIR were fixed in
4% (v/v) paraformaldehyde, dehydrated by a series of incubations
in 30, 50, and 70% (v/v) ethanol, and dried on aluminum support
for SEM. EVs isolated were coated with gold. A SEM LEO 1450VP
(Carl Zeiss Meditec, Oberkochen, Germany) was employed to
acquire backscattered electron images using 20 keV electrons
leading to an information depth of about 1.5 lm. Images with a
scan size of 30 × 30 lm were acquired, at a resolution of
1,024 × 1,024 pixels.
EVs labeling
Acridine orange
To detect nucleic acid content, FAP-derived EVs (10 lg) isolated by
TEIR were labeled with acridine orange (AO) (#235474, Sigma)
(0.1 lg/ml) for 30 min at room temperature and added to MuSCs in
order to reveal by immunofluorescence the RNA exchanged from
FAPs to MuSCs.
Pkh-67
To visualize EVs, FAP-derived EVs (10 lg) are stained for 5 min at
room temperature RT with 0.5 ll of PKH67 Green Fluorescent Cell
Linker Kit for General Cell Membrane Labeling (#P7333, Sigma) and
then polished with the exosome spin columns (#4484449, Invitrogen
by Thermo Fisher Scientific) following the manufacturer’s protocol.
The stained EVs are detected by immunofluorescence into
myofibers and by cyto-fluorimetric analysis in mouse muscle after
their in vivo injection.
Flow cytometric analysis of extracellular vesicles released by FAPs
EVs purified from FAPs isolated from mdx mice and treated with
DMSO (CTR) and TSA (50 nM) were stained with PKH67 dye and
acquired on the CytoFLEX flow cytometer (Beckman Coulter, Brea,
CA, USA). The cytometer was calibrated using a mixture of non-
fluorescent silica beads and fluorescent (green) latex beads (Apogee,
UK) with sizes ranging from 110 to 1,300 nm. This calibration step
enabled the determination of the sensitivity and resolution of the flow
cytometer (fluorescent latex beads) and the size of extracellular vesi-
cles (silica beads) (Logozzi et al, 2017). All samples were acquired at
low flow rate for the same amount of time (1 min) in order to obtain
an estimate of absolute counts of microvesicles comparable between
various samples. The analysis of the data was performed with FlowJo
software (FlowJo, LLC; Ashland, Oregon, USA). The FAPs were puri-
fied by FACS and seeded under the same condition and in the same
number for all the samples analyzed. For EV isolation and labeling,
all the samples were treated in the same way.
EV content
Protein
EVs isolated were lysed for protein extraction in RIPA buffer
(50 mM Tris–HCl, pH 7.4; 150 mM NaCl; 1% NP-40; protease inhi-
bitors). The total extravesicular protein content was quantified
using the micro bicinchoninic acid protein assay (BCA) (#23235,
Thermo Fisher Scientific).
Western blot
Western blot was performed on 12 ug of total lysate (WCL) and of
EV proteins using antibodies against the following proteins: rabbit
anti-CD63 (1/300, H-193, Santa Cruz Biotechnology), mouse anti-
Hsp70 (1/2,500, clone BRM-22, Sigma-Aldrich), rabbit anti-Calnexin
(CANX) (1/1,000, NB100-1965, Novus Biologicals), rabbit anti-
Flotillin-1 (1/200, H-104, Santa Cruz Biotechnology), mouse anti-
Alix (3A9) (1/500, Cell Signaling Technologies #2171), and mouse
ª 2020 The Authors EMBO reports e50863 | 2020 15 of 19
Martina Sandonà et al EMBO reports
monoclonal Col3a1 (B-10) (1/150, Santa Cruz Biotechnologies,
#sc-271249).
As total lysate normalization, we used Ponceau quantification.
microRNA
Total extravesicular RNA was extracted with Total Exosome RNA
Protein Isolation Kit (#4478545, Thermo Fisher Scientific). TaqMan
MicroRNA Assays were performed according to the manufacturer’s
recommended protocols (Applied Biosystems). The threshold cycle
(Ct) was defined as the fractional cycle number at which the fluores-
cence passes the fixed threshold. U6 snRNA served as an endoge-
nous control for normalization.
In particular, total EVs-RNA was retro-transcribed using TaqMan
MicroRNA Reverse Transcription Kit (#4366596, Thermo Fisher
Scientific).
For greater sensitivity, the cDNA was pre-amplified using
TaqMan PREAMP Master Mix (#4391128, Thermo Fisher Scientific)
and Megaplex PreAMP Primers and then amplified using high-multi-
plexed Megaplex Primer Pool (#4444766, Thermo Fisher Scientific)
and the TaqMan 2× Universal Master Mix II (#4440040, Thermo
Fisher Scientific) on TaqMan Rodent MicroRNA A/B Cards Array
version 3.0 (#4444909, Thermo Fisher Scientific).
qRT–PCR
For microRNA validation, total EVs-RNA was extracted with Total
Exosome RNA Protein Isolation Kit (#4478545, Invitrogen by Thermo
Fisher Scientific) and was retro-transcribed using the Qiagen Reverse
Transcription Kit (miScript II RT Kit, #218161, Qiagen) and pre-ampli-
fied using miScript PreAMP PCR Kit (#331451, Qiagen).
Real-time qPCR was performed using miScript SYBR Green PCR
Kit (#218073, Qiagen) and using primers reported in Table 1. All the
conditions are provided in the manufacturer’s protocol.
FAP-derived EV intramuscular injection
FAP-derived EVs at a final concentration of 10 lg in 20 ll of PBS 1×
(0.5 lg/ll) were injected 3 times in left tibialis anterior (TA) of
C57BL/6/mdx mice: every 7 days for 21 days. The right TA was
injected with vehicle (20 ll PBS 1×) following the same timing
described for EV injection.
RNA sequencing
For RNA-sequencing sample preparation, MuSCs and FAPs were
freshly isolated by FACS from 6 C57BL/6 mdx male mice of 8 weeks
old treated or not with TSA for 15 days. RNA was collected using
TRIzol reagent (#T9424, Sigma). About 100 ng/ll of total RNA was
sent in duplicate to IGA (Istituto di Genomica Applicata, Udine) for
RNA sequencing using Illumina TruSeq Stranded Total RNA Kit
Ribo-Zero GOLD on Illumina HiSeq 2500 platform.
Statistical analysis
The number of independent experimental replications and precision
measures are reported in the figure legends (n, mean  SEM).
Statistical analysis was performed using Prism 7.0 A software
(Pad Software).
Most of the data meet the assumptions of the tests (e.g., normal
distribution). Whether data do not meet the assumptions of the tests
(e.g., normal distribution), Mann–Whitney’s test was used as non-
parametric test. For the assumption of normality, we used Shapiro–
Wilk normality test; unpaired, two-tailed Student’s t-test was used
to compare the means of two groups; and Welch’s correction was
applied to account for unequal variances, while one-way analysis of
variance (ANOVA) was used for comparison among the different
groups, while two-way analysis of variance was used for compar-
ison among different groups to examine the influence of dif-
ferent independent variables on dependent variable. When ANOVA
was significant, post hoc testing of differences between groups was
performed using Tukey’s honestly significant difference (HSD). A
P < 0.05 was considered statistically significant.
For animal studies, the sample size was calculated by power
analysis. The animal experiments were not randomized. The investi-
gators were not blinded to allocation during experiments and
outcome assessment. No exclusion criteria were applied to exclude
samples or animals from analysis.
Data acquisition, analysis, and quantification
The cells positive for the stainings described in the text were quanti-
fied using ImageJ software (https://imagej.nih.gov/ij/download.
html). The cross-sectional area (CSA) was also calculated using the
ImageJ software and Macro seg 5 modif.ijm specific plugin. Fibrotic
areas were measured from sections evaluating image analysis algo-
rithms for color deconvolution. ImageJ was used for image processing,
the original image was segmented with three clusters, and the plugin
assumes images generated by color subtraction (white representing
background, blue collagen, and magenta non-collagen regions).
FACS profile analysis of MuSCs and FAPs was performed using
FlowJo software (https://www.flowjo.com).
RNA-seq
The RNA-sequencing analysis was performed mapping more than
20 millions of reads for each sample to the Mus Musculus
GRCm38.78 genome using TopHat 2.0.9. Read count was performed
with HTSeq-0.6.1p1. Mapped reads were analyzed with RStudio
using DESeq2 to obtain normalized RPKM, P-value, P-adjusted, and
log2 fold change values. Genes were considered differentially
expressed if the P-adjusted value was < 0.1.
Additional raw data that support the findings of this study are
available from the corresponding authors upon reasonable request.
RNA-seq data are available through SRA accession code SRP143532
(Iannotti et al, 2018).
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miRNA’s targets analysis
miRNA pathway analysis was performed using miRPath based on
predicted miRNA targets provided by the DIANA-microT-CDS
algorithm and/or experimentally validated miRNA interactions
derived from DIANA-TarBase v6.0 (http://www.microrna.gr/
miRPathv2).
Prediction of miRNA-mRNA interactions and network construction
Data from RNA-seq (Padj < 0.1) in MuSCs (treated or not with TSA)
and microarray analysis in FAP (treated or not with TSA)-derived
EVs were uploaded in IPA (https://www.qiagenbioinformatics.com/
products/ingenuity-pathway-analysis/). With the IPA tool “miR
Target Filter”, the miRNA up-regulated in FAPs-EVs was intersected
with transcripts down-regulated in MuSCs after TSA treatment. Only
interactions experimentally observed and highly predicted were
selected for downstream analysis. Notch pathway was extrapolated
from IPA database using the tool “grow”, while its modulation was
predicted by the Molecular Activity Predictor (MAP) tool. The
cartoon was realized with IPA Path Designer.
Data availability
No new primary datasets have been generated and deposited in
this study.
Expanded View for this article is available online.
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